Novel Fibrinogen Bβ Gene Mutation Causing Hypofibrinogenaemia

• References

• 1 Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation site from fibrinogen Canterbury (Aα20 Val→Asp). J Clin Invest 1995; 96: 2854-8.
• 2 Brennan SO. Electrospray ionisation analysis of human fibrinogen. Thromb Haemost 1997; 78: 1055-8.
• 3 Saiki RK, Chang CA, Levenson CH, Warren TC, Boehm CD, Kazazian Jr HH, Erlich HA. Diagnosis of sickle cell anemia and beta-thalassemia with enzymatically amplified DNA and nonradioactive allele-specific oligonucleotide probes. N Engl J Med 1988; 319: 537-41.
• 4 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389 6650 455-62.
• 5 Brennan SO, Wyatt JM, May S, De Caigney S, George PM. Hypofibrinogenemia due to novel 316 Asp → Tyr substitution in the fibrinogen Bβ chain. Thromb Haemost 2001; 85: 450-3.
• 6 Zhang JZ, Redman CM. Identification of Bβ chain domains involved in human fibrinogen assembly. J Biol Chem 1992; 267: 21727-32.
• 7 Homer VM, Brennan SO, Ockelford P, George PM. Novel Fibrinogen truncation with deletion of Bβ chain residues 440-461 causes hypofibrinogenaemia. Thromb Haemost 2002; 88: 427-31.